30Sep 2022
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study

In this study, in a high-risk population of patients admitted for COVID-19, the study found an earlier time to hospital discharge among participants receiving CCP with nAb titers of >1:640 compared with participants receiving CCP with a lower nAb titer and no CCP-related AEs. The significance of this research is in identifying a dose-response of CCP and clinical outcomes based on nAb titer. Although limited by the small study size, these findings support further study of high-nAb-titer CCP defined as >1:640 in the treatment of COVID-19.

  • #family health

Like

Save

Share